Skribe Medical advances wearable heart monitoring for cancer patients following selection for FDA innovation program
SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Skribe Medical, a U.S. medical technology company developing wearable cardiac monitoring for cancer care, today announced progress in its clinical development program following selection of its Aurora System for the U.S. Food and Drug...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.